Incisional negative pressure wound therapy for preoperatively irradiated lower extremity soft tissue sarcoma wounds. A prospective randomized clinical trial. Save

Date Added
August 18th, 2015
PRO Number
Pro00028423
Researcher
Lee Leddy

Silhouette
Keywords
Cancer, Cancer/Sarcoma, Infectious Diseases
Summary

This is a study comparing two methods of dressing a post operative wound that are currently in practice. One method is a traditional dry gauze dressing. The other method is using a negative pressure dressing that provides gentle suction on the wound.

We will attempt to determine how well the use of post-operative negative pressure dressing reduces wound healing problems in patients who have surgery after radiation for a sarcoma in the thigh or leg.

Institution
MUSC
Recruitment Contact
Jennifer Philp
843 8462210
Philp, Jennifer (philpj@musc.edu)

Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI) Save

Date Added
May 20th, 2014
PRO Number
Pro00034264
Researcher
Steven Carroll

Silhouette
Keywords
Cancer, Cancer/Sarcoma
Summary

This study is for adult males and females who are being treated for cancer. This study inovlves collecting samples and saving them for future research.

Institution
MUSC
Recruitment Contact
Scott Landreth
843-792-6429
landrets@musc.edu

A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma. Save

Date Added
March 13th, 2012
PRO Number
Pro00015882
Researcher
Daniel Reuben

Silhouette
Keywords
Cancer, Cancer/Sarcoma
Summary

The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma. Screening tests will be done to ensure subjects are eligible to participate in this study. If the exams, tests and procedures show that subjects can be in the study, and they choose to take part, then they will be "randomized" into one of the two study groups: Group 1 or Group 2. Subjects in Group 1 will receive Gemcitabine 1000 mg/m2 intravenously (directly into a vein) on Day 1 and Day 8 and Pazopanib 800mg by mouth daily. Subjects in Group 2 will receive Gemcitabine 900 mg/m2 intravenouslyon Day 1 and Day 8 and Docetaxel 100 mg/m2 intravenously on Day 8. Both groups will be in 21 day cycles. Both groups will be asked to complete 2 "quality of life" questionnaires, on their first visit, then at 6 weeks (2nd cycle), 18 weeks (6th cycle) and at the end of study treatment. Subjects will be followed for up to 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Circulating Fibroblast Precursors in Metastatic Sarcoma Save

Date Added
June 22nd, 2011
PRO Number
Pro00010978
Researcher
Amanda Larue

Silhouette
Keywords
Cancer, Cancer/Sarcoma
Summary

The purpose of this project is to determine the role of fibroblasts in sarcoma metastasis. Fibroblasts are cells that are major component of the supporting and connecting structures of the body. Precursors to these tissue fibroblasts are found in our bone marrow and in our circulating blood. The study doctor will grow fibroblasts from blood samples in culture and determine the role that they play in promoting tumor cell invasion and metastasis.

Institution
MUSC
Recruitment Contact
Sara Rothmyer
843-792-1507
rothmyer@musc.edu

Change_preferences

-- OR --

Create_login